608 related articles for article (PubMed ID: 28100438)
1. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
[TBL] [Abstract][Full Text] [Related]
2. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
3. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
[TBL] [Abstract][Full Text] [Related]
4. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
[TBL] [Abstract][Full Text] [Related]
6. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Gillespie SH; Crook AM; McHugh TD; Mendel CM; Meredith SK; Murray SR; Pappas F; Phillips PP; Nunn AJ;
N Engl J Med; 2014 Oct; 371(17):1577-87. PubMed ID: 25196020
[TBL] [Abstract][Full Text] [Related]
7. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Jindani A; Harrison TS; Nunn AJ; Phillips PP; Churchyard GJ; Charalambous S; Hatherill M; Geldenhuys H; McIlleron HM; Zvada SP; Mungofa S; Shah NA; Zizhou S; Magweta L; Shepherd J; Nyirenda S; van Dijk JH; Clouting HE; Coleman D; Bateson AL; McHugh TD; Butcher PD; Mitchison DA;
N Engl J Med; 2014 Oct; 371(17):1599-608. PubMed ID: 25337749
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
[TBL] [Abstract][Full Text] [Related]
9. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
Lee JK; Lee JY; Kim DK; Yoon HI; Jeong I; Heo EY; Park YS; Jo YS; Lee JH; Park SS; Park JS; Kim J; Lee SM; Joh JS; Lee CH; Lee J; Choi SM; Park JH; Lee SH; Cho YJ; Lee YJ; Kim SJ; Kwak N; Hwang YR; Kim H; Ki J; Lim JN; Choi HS; Lee M; Song T; Kim HS; Han J; Ahn H; Hahn S; Yim JJ
Lancet Infect Dis; 2019 Jan; 19(1):46-55. PubMed ID: 30477961
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
Cross GB; Sari IP; Kityo C; Lu Q; Pokharkar Y; Moorakonda RB; Thi HN; Do Q; Dalay VB; Gutierrez E; Balanag VM; Castillo RJ; Mugerwa H; Fanusi F; Kwan P; Chew KL; Paton NI;
Lancet Infect Dis; 2023 Jul; 23(7):847-855. PubMed ID: 36966799
[TBL] [Abstract][Full Text] [Related]
11. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
[TBL] [Abstract][Full Text] [Related]
12. Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial.
Diacon A; Miyahara S; Dawson R; Sun X; Hogg E; Donahue K; Urbanowski M; De Jager V; Fletcher CV; Hafner R; Swindells S; Bishai W
Lancet Microbe; 2020 Jun; 1(2):e84-e92. PubMed ID: 33834177
[TBL] [Abstract][Full Text] [Related]
13. A four-month gatifloxacin-containing regimen for treating tuberculosis.
Merle CS; Fielding K; Sow OB; Gninafon M; Lo MB; Mthiyane T; Odhiambo J; Amukoye E; Bah B; Kassa F; N'Diaye A; Rustomjee R; de Jong BC; Horton J; Perronne C; Sismanidis C; Lapujade O; Olliaro PL; Lienhardt C;
N Engl J Med; 2014 Oct; 371(17):1588-98. PubMed ID: 25337748
[TBL] [Abstract][Full Text] [Related]
14. Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
Dooley KE; Hendricks B; Gupte N; Barnes G; Narunsky K; Whitelaw C; Smit T; Ignatius EH; Friedman A; Dorman SE; Dawson R;
Am J Respir Crit Care Med; 2023 Apr; 207(7):929-935. PubMed ID: 36455068
[No Abstract] [Full Text] [Related]
15. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
Lancet Infect Dis; 2024 May; ():. PubMed ID: 38768617
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
Ziganshina LE; Titarenko AF; Davies GR
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD004795. PubMed ID: 23744519
[TBL] [Abstract][Full Text] [Related]
17. Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI; Cousins C; Suresh C; Burhan E; Chew KL; Dalay VB; Lu Q; Kusmiati T; Balanag VM; Lee SL; Ruslami R; Pokharkar Y; Djaharuddin I; Sugiri JJR; Veto RS; Sekaggya-Wiltshire C; Avihingsanon A; Sarin R; Papineni P; Nunn AJ; Crook AM;
N Engl J Med; 2023 Mar; 388(10):873-887. PubMed ID: 36808186
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of intensified short course regimen and standard regimen for adults TB meningitis: a protocol for an open label, multi-center, parallel arms, randomized controlled superiority trial (INSHORT trial).
Inbaraj LR; Manesh A; Ponnuraja C; Bhaskar A; Srinivasalu VA; Daniel BD
Trials; 2024 May; 25(1):294. PubMed ID: 38693583
[TBL] [Abstract][Full Text] [Related]
19. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
Velayutham BV; Allaudeen IS; Sivaramakrishnan GN; Perumal V; Nair D; Chinnaiyan P; Paramasivam PK; Dhanaraj B; Santhanakrishnan RK; Navaneethapandian GP; Marimuthu MK; Kumar V; Kandasamy C; Dharuman K; Elangovan T; Narasimhan M; Rathinam S; Vadivelu G; Rathinam P; Chockalingam C; Jayabal L; Swaminathan S; Shaheed JM
Clin Infect Dis; 2014 Nov; 59(10):e142-9. PubMed ID: 25028463
[TBL] [Abstract][Full Text] [Related]
20. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
